An interventional study of DEX 0.2 μg/kg/h. and SGB in Uterine Fibroids (Leiomyoma), Adenomyosis of Uterus and Endometriosis, sponsored by Catherin Zhang. Recruiting at 1 site in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Catherin Zhang · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Leiomyoma with a site in China — 20 open to participants now, 23 under way, 2 of them phase 3. Leiomyoma · China.
Among the 40 studies in Leiomyoma with a site in China, this one is the 20th largest by planned enrollment of the 29 interventional ones that give a count, is one of 5 that started in 2026, is one of 15 with no phase, reaches primary completion later than 14 of the 22 other live ones, and was the 39th registered.
439 studies on the registry are indexed under Leiomyoma; 74 are open to participants now.
Browse Leiomyoma studies →20 of the 40 studies in Leiomyoma with a site in China are open now. Recruiting first, the newest first:
Peking University Aerospace Center Hospital · Sites in China
Women only
Shenzhen Kangzhe Biotechnology Co., Ltd. · Sites in China
Ages 18–50 · Women only
Zhejiang University · Sites in China
Ages 18–65 · Women only
Huazhong University of Science and Technology · Sites in China
Ages 18+
The Fourth Affiliated Hospital of Zhejiang University School of Medicine · Sites in China
Ages 18–50 · Women only
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 44 Leiomyoma studies recruiting now, 23 (52%) set no upper age limit and 20 (45%) stop at 75 or younger; 4 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 75 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 7 · Phase 4 3
First in 2008; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 66 across 307 interventional studies indexed under Leiomyoma.
Median enrollment 120 across the 29 interventional studies, 200 across the 11 observational. Of the 9 that completed or were terminated, 2 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 40 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Catherin Zhang as lead sponsor.
Catherin Zhang has 1 study filed under Leiomyoma — fewer than ten, so there is no comparison to draw.
7 of the studies in Leiomyoma with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07860203Catherin ZhangStellate Ganglion Block and Dexmedetomidine for Postoperative Sleep in Women Undergoing Laparoscopic Gynecologic Surgery | 2026-12 |
| NCT06828419Second Affiliated Hospital of Wenzhou Medical UniversityA Clinical Study on the Feasibility and Safety of Abdominal Endoscopic Single-port Surgery System to Assist Gynecological Day Surgery | 2026-12-31 |
| NCT06020924Wenwen WangThe Effects of Uterine Fibroids on Pregnancy in Women | 2026-12-31 |
| NCT05840042Wenwen WangEpidemiology and Risk Factors of Uterine Fibroids in China | 2026-12-31 |
| NCT05386615InSightecPost-Exablate Pregnancy Outcomes Registry Study: Exablate Treatment of Symptomatic Uterine Fibroids | 2026-12-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 40 studies in Leiomyoma with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Study Objectives This study aims to investigate the effects of preoperative stellate ganglion block and intraoperative intravenous dexmedetomidine on postoperative sleep disturbance in patients undergoing laparoscopic gynecologic surgery, with the goals of reducing pain and postoperative adverse reactions and identifying an effective, safe, economical, and broadly applicable intervention strategy that may facilitate emergence from anesthesia, accelerate postoperative recovery, shorten the length of hospital stay, and reduce hospitalization costs.
This trial aims to determine whether preoperative stellate ganglion block (SGB) and intraoperative intravenous dexmedetomidine (DEX) can improve postoperative sleep quality in patients undergoing laparoscopic gynecologic surgery, and whether the combination of these two interventions provides an interaction effect or additional ben
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stellate ganglion block + dexmedetomidine
Drug: DEX 0.2 μg/kg/h. · Procedure: SGB
Stellate ganglion block + 0.9% sodium chloride
Procedure: SGB · Drug: 0.9% Sodium Chloride (Placebo)
Sham stellate ganglion block + dexmedetomidine
Drug: DEX 0.2 μg/kg/h. · Procedure: Sham Stellate Ganglion Block
Sham stellate ganglion block + 0.9% sodium chloride
Drug: 0.9% Sodium Chloride (Placebo) · Procedure: Sham Stellate Ganglion Block
Drug page: DextromethorphanStudies of DextromethorphanDextromethorphan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Dexmedetomidine is administered by intravenous infusion after induction of anesthesia without a loading dose, at an infusion rate of 0.2μg·kg-¹·h-¹, and continued until the end of surgery.
Stellate ganglion block (SGB) is performed 15 min after induction of anesthesia by an anesthesiologist experienced in ultrasound-guided regional anesthesia, who is aware of the patient's group assignment. The patient is placed in the supine position with the neck slightly extended and rotated to the contralateral side. Under sterile conditions, a high-frequency linear-array ultrasound transducer is used to scan the anterior neck transversely at the C6 level, sequentially identifying the common carotid artery, internal jugular vein, thyroid gland, esophagus, C6 transverse process and anterior tubercle, longus colli muscle, and surrounding vascular structures. In the SGB group, an in-plane needle approach is used under real-time ultrasound guidance. After the needle tip reaches the fascial plane anterior to the longus colli muscle and negative aspiration for blood is confirmed, 5 mL of 0.375% ropivacaine is injected slowly. Spread of the local anesthetic along the surface of the longus
An equal volume of 0.9% sodium chloride solution is administered by intravenous infusion after induction of anesthesia as a placebo for dexmedetomidine and continued until the end of surgery.
Participants are placed in the same position as those receiving the stellate ganglion block, and the ultrasound probe is placed on the neck in an identical manner to simulate the procedure. No needle puncture or drug injection is performed.
St. Mary's Hospital Sleep Questionnaire Score 1 Day Before Surgery
Subjective sleep quality is assessed using the St. Mary's Hospital Sleep Questionnaire (SMHSQ). The total score ranges from 11 to 37, with higher scores indicating poorer sleep quality.
Time frame: 1 day before surgery(ΡRE)
Total Sleep Time 1 Day Before Surgery
Total sleep time (TST), expressed in minutes, is objectively measured using a Fitbit Charge 6 wrist-worn device.
Time frame: 1 day before surgery(PRE)
Wake After Sleep Onset 1 Day Before Surgery
Wake after sleep onset is the total duration of wakefulness after initial sleep onset during the assessed sleep period, measured in minutes using a Fitbit Charge 6 wrist-worn device.
Time frame: 1 day before surgery(PRE)
Sleep Efficiency 1 Day Before Surgery
Sleep efficiency is calculated as total sleep time (TST) divided by the sum of total sleep time and wake after sleep onset (WASO), multiplied by 100. TST and WASO are obtained using a Fitbit Charge 6 wrist-worn device. Values range from 0% to 100%, with higher values indicating a greater proportion of the assessed sleep period spent asleep.
Time frame: 1 day before surgery(PRE)
St. Mary's Hospital Sleep Questionnaire Score on Postoperative Day 1
Subjective sleep quality is assessed using the St. Mary's Hospital Sleep Questionnaire (SMHSQ). The total score ranges from 11 to 37, with higher scores indicating poorer sleep quality.
Time frame: Postoperative Day 1(POD1)
Total Sleep Time on Postoperative Day 1
Total sleep time (TST), expressed in minutes, is objectively measured using a Fitbit Charge 6 wrist-worn device.
Time frame: Postoperative day 1
Wake After Sleep Onset on Postoperative Day 1
Wake after sleep onset is the total duration of wakefulness after initial sleep onset during the assessed sleep period, measured in minutes using a Fitbit Charge 6 wrist-worn device.
Time frame: Postoperative day 1(ΡOD1)
Sleep Efficiency on Postoperative Day 1
Sleep efficiency is calculated as total sleep time (TST) divided by the sum of total sleep time and wake after sleep onset (WASO), multiplied by 100. TST and WASO are obtained using a Fitbit Charge 6 wrist-worn device. Values range from 0% to 100%, with higher values indicating a greater proportion of the assessed sleep period spent asleep.
Time frame: Postoperative day 1(ΡOD1)
St. Mary's Hospital Sleep Questionnaire Score on Postoperative Day 2
Subjective sleep quality is assessed using the St. Mary's Hospital Sleep Questionnaire (SMHSQ). The total score ranges from 11 to 37, with higher scores indicating poorer sleep quality.
Time frame: Postoperative Day 2(ΡOD2)
Total Sleep Time on Postoperative Day 2
Total sleep time (TST), expressed in minutes, is objectively measured using a Fitbit Charge 6 wrist-worn device.
Time frame: Postoperative day 2
Wake After Sleep Onset on Postoperative Day 2
Wake after sleep onset is the total duration of wakefulness after initial sleep onset during the assessed sleep period, measured in minutes using a Fitbit Charge 6 wrist-worn device.
Time frame: Postoperative day 2(POD2)
Sleep Efficiency on Postoperative Day 2
Sleep efficiency is calculated as total sleep time (TST) divided by the sum of total sleep time and wake after sleep onset (WASO), multiplied by 100. TST and WASO are obtained using a Fitbit Charge 6 wrist-worn device. Values range from 0% to 100%, with higher values indicating a greater proportion of the assessed sleep period spent asleep.
Time frame: Postoperative day 2(POD2)
Postoperative Pain Intensity at 6 Hours
Postoperative pain intensity is assessed using the Visual Analog Scale. Scores range from 0 to 10, with 0 indicating no pain and 10 indicating the worst imaginable pain. Higher scores indicate greater pain intensity.
Time frame: 6 hours after surgery
Postoperative Pain Intensity at 24 Hours
Postoperative pain intensity is assessed using the Visual Analog Scale. Scores range from 0 to 10, with 0 indicating no pain and 10 indicating the worst imaginable pain. Higher scores indicate greater pain intensity.
Time frame: 24 hours after surgery
Postoperative Pain Intensity at 48 Hours
Postoperative pain intensity is assessed using the Visual Analog Scale. Scores range from 0 to 10, with 0 indicating no pain and 10 indicating the worst imaginable pain. Higher scores indicate greater pain intensity.
Time frame: 48 hours after surgery
Total Intraoperative Sufentanil Consumption
The cumulative dose of sufentanil administered to each participant from induction of anesthesia to the end of surgery is recorded in micrograms.
Time frame: From induction of anesthesia to the end of surgery
Total Intraoperative Remifentanil Consumption
The cumulative dose of remifentanil administered to each participant from induction of anesthesia to the end of surgery is recorded in milligrams.
Time frame: From induction of anesthesia to the end of surgery
Number of Rescue Analgesia Administrations
The total number of rescue analgesia administrations received by each participant during the first 48 hours after surgery is recorded.
Time frame: From the end of surgery to 48 hours after surgery.
Mean Arterial Pressure
Mean arterial pressure (MAP), expressed in mmHg, is recorded at five prespecified time points to assess perioperative hemodynamic changes.
Time frame: Before induction of anesthesia (T0), at skin incision (T1), 30 minutes after the start of surgery (T2), 60 minutes after the start of surgery (T3), and at the end of surgery (T4).
Heart Rate
Heart rate (HR), expressed in beats per minute, is recorded at five prespecified time points to assess perioperative hemodynamic changes.
Time frame: Before induction of anesthesia (T0), at skin incision (T1), 30 minutes after the start of surgery (T2), 60 minutes after the start of surgery (T3), and at the end of surgery (T4).
Number of Participants With Local Anesthetic Systemic Toxicity
The number of participants who experience local anesthetic systemic toxicity is recorded. Each participant is counted once, regardless of the number of episodes.
Time frame: From administration of the first study intervention to 48 hours after surgery.
Number of Participants With Puncture-Site Hematoma
The number of participants who develop a puncture-site hematoma is recorded. Each participant is counted once, regardless of the number of episodes.
Time frame: From administration of the first study intervention to 48 hours after surgery.
Number of Participants With Puncture-Site Infection
The number of participants who develop a puncture-site infection is recorded. Each participant is counted once, regardless of the number of episodes.
Time frame: From administration of the first study intervention to 48 hours after surgery.
Number of Participants With Unintended Nerve Block
The number of participants who experience an unintended nerve block is recorded. Each participant is counted once, regardless of the number of episodes.
Time frame: From administration of the first study intervention to 48 hours after surgery.
Number of Participants With Pneumothorax
The number of participants who develop pneumothorax is recorded. Each participant is counted once, regardless of the number of episodes.
Time frame: From administration of the first study intervention to 48 hours after surgery.
Number of Participants With Bradycardia
The number of participants who experience bradycardia is recorded. Each participant is counted once, regardless of the number of episodes.
Time frame: From administration of the first study intervention to 48 hours after surgery.
Number of Participants With Hypotension
The number of participants who experience hypotension is recorded. Each participant is counted once, regardless of the number of episodes.
Time frame: From administration of the first study intervention to 48 hours after surgery.
Number of Participants With Hypoxemia
The number of participants who experience hypoxemia is recorded. Each participant is counted once, regardless of the number of episodes.
Time frame: From administration of the first study intervention to 48 hours after surgery.
Number of Participants With Postoperative Nausea or Vomiting
The number of participants who experience nausea, vomiting, or both during the first 48 hours after surgery is recorded. Each participant is counted once, regardless of the number of episodes or whether both symptoms occur.
Time frame: From the end of surgery to 48 hours after surgery.
Number of Participants With Postoperative Headache or Dizziness
The number of participants who experience headache, dizziness, or both during the first 48 hours after surgery is recorded. Each participant is counted once, regardless of the number of episodes or whether both symptoms occur.
Time frame: From the end of surgery to 48 hours after surgery.
Number of Participants With Postoperative Nightmares or Excessive Dreaming
The number of participants who report nightmares, excessive dreaming, or both during the first 48 hours after surgery is recorded. Each participant is counted once, regardless of the number of episodes or whether both symptoms occur.
Time frame: From the end of surgery to 48 hours after surgery.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Start is estimated for Oct 2026; primary completion for Dec 2026, 2 months later.
Of 53 non-industry interventional studies with no phase under Leiomyoma, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 43. This study's planned 2 months is below that.
Counting every sponsor, half of 58 studies reached it within 31 months; a quarter within 15 and three quarters within 72.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dextromethorphan